Overview

PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer

Status:
Withdrawn
Trial end date:
2020-12-01
Target enrollment:
0
Participant gender:
Male
Summary
This study will evaluate the safety of PD-1 knockout engineered T cells in treating castration resistant prostate cancer (CRPC). Blood samples will also be collected for research purposes.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Peking University
Collaborator:
Cell Biotech Co., Ltd.
Treatments:
Cyclophosphamide
Interleukin-2
Polystyrene sulfonic acid
Criteria
Inclusion Criteria:

- Pathologically and clinical verified castration resistant prostate cancer with
measurable lesions (On CT: longest diameter of tumoral lesion >=10 mm, shorted
diameter of lymph node >=15 mm; measurable lesions should not have been irradiated)

- Progressed after all standard treatment

- Performance score: 0-1

- Expected life span: >= 6 months

- Toxicities from prior treatment has resolved. Washout period is 4 weeks for
chemotherapy, and 2 weeks for targeted therapy

- Major organs function normally

- Willing and able to provide informed consent

Exclusion Criteria:

- Pathology is mixed type

- Emergent treatment of tumor emergency is needed

- Poor vasculature

- Coagulopathy, or ongoing thrombolytics and/or anticoagulation

- Blood-borne infectious disease, e.g. hepatitis B

- History of mandatory custody because of psychosis or other psychological disease
inappropriate for treatment deemed by treating physician

- With other immune diseases, or chronic use of immunosuppressants or steroids

- Compliance cannot be expected

- Other conditions requiring exclusion deemed by physician